Top

Breast Cancer Research

Published in:

01-12-2021 | Metastasis | Research article

Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment

Authors: Simion C. Dinca, Daniel Greiner, Keren Weidenfeld, Laura Bond, Dalit Barkan, Cheryl L. Jorcyk

Published in: Breast Cancer Research | Issue 1/2021

Abstract

Background

Invasive ductal carcinoma (IDC) is a serious problem for patients as it metastasizes, decreasing 5-year patient survival from > 95 to ~ 27%. The breast tumor microenvironment (TME) is often saturated with proinflammatory cytokines, such as oncostatin M (OSM), which promote epithelial-to-mesenchymal transitions (EMT) in IDC and increased metastasis. The extracellular matrix (ECM) also plays an important role in promoting invasive and metastatic potential of IDC. Specifically, the reorganization and alignment of collagen fibers in stromal ECM leads to directed tumor cell motility, which promotes metastasis. Lysyl oxidase like-2 (LOXL2) catalyzes ECM remodeling by crosslinking of collagen I in the ECM. We propose a novel mechanism whereby OSM induces LOXL2 expression, mediating stromal ECM remodeling of the breast TME.

Methods

Bioinformatics was utilized to determine survival and gene correlation in patients. IDC cell lines were treated with OSM (also IL-6, LIF, and IL-1β) and analyzed for LOXL2 expression by qRT-PCR and immunolabelling techniques. Collagen I contraction assays, 3D invasion assays, and confocal microscopy were performed with and without LOXL2 inhibition to determine the impact of OSM-induced LOXL2 on the ECM.

Results

Our studies demonstrate that IDC patients with high LOXL2 and OSM co-expression had worse rates of metastasis-free survival than those with high levels of either, individually, and LOXL2 expression is positively correlated to OSM/OSM receptor (OSMR) expression in IDC patients. Furthermore, human IDC cells treated with OSM resulted in a significant increase in LOXL2 mRNA, which led to upregulated protein expression of secreted, glycosylated, and enzymatically active LOXL2. The expression of LOXL2 in IDC cells did not affect OSM-promoted EMT, and LOXL2 was localized to the cytoplasm and/or secreted. OSM-induced LOXL2 promoted an increase in ECM collagen I fiber crosslinking, which led to significant fiber alignment between cells and increased IDC cell invasion.

Conclusions

Aligned collagen fibers in the ECM provide pathways for tumor cells to migrate more easily through the stroma to nearby vasculature and tissue. These results provide a new paradigm through which proinflammatory cytokine OSM promotes tumor progression. Understanding the nuances in IDC metastasis will lead to better potential therapeutics to combat against the possibility.

Available only for authorised users

Kuukasjarvi T, Tanner M, Pennanen S, Karhu R, Kallioniemi OP, Isola J. Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol (Article). 1997;150:1465–71.

Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review. Natl Canc Inst. 1975–2016.

Grenier A, Dehoux M, Boutten A, Arce-Vicioso M, Durand G, Gougerot-Pocidalo MA, et al. Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood. 1999;93(4):1413–21. https://doi.org/10.1182/blood.V93.4.1413.CrossRefPubMed

Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res (Article). 2005;65(19):8896–904. https://doi.org/10.1158/0008-5472.CAN-05-1734.CrossRef

Hurst SM, McLoughlin RM, Monslow J, Owens S, Morgan L, Fuller GM, et al. Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells. J Immunol. 2002;169(9):5244–51. https://doi.org/10.4049/jimmunol.169.9.5244.CrossRefPubMed

Adrian-Segarra JM, Schindler N, Gajawada P, Loerchner H, Braun T, Poeling J. The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation. J Biol Chem. 2018;293(18):7017–29. https://doi.org/10.1074/jbc.RA118.001920.CrossRefPubMedPubMedCentral

Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical Journal. 2003;374(1):1–20. https://doi.org/10.1042/bj20030407.CrossRefPubMedCentralPubMed

Liu JW, Hadjokas N, Mosley B, Estrov Z, Spence MJ, Vestal RE. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine. 1998;10(4):295–302. https://doi.org/10.1006/cyto.1997.0283.CrossRefPubMed

Tawara K, Bolin C, Koncinsky J, Kadaba S, Covert H, Sutherland C, et al. OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung. Breast Cancer Res. 2018;20(53):1–18. https://doi.org/10.1186/s13058-018-0971-5.

10.

Guo YQ, Xu F, Lu TJ, Duan ZF, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38(7):904–10. https://doi.org/10.1016/j.ctrv.2012.04.007.CrossRefPubMed

11.

Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009;28(33):2940–7. https://doi.org/10.1038/onc.2009.180.CrossRefPubMedPubMedCentral

12.

Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117(12):3988–4002. https://doi.org/10.1172/JCI32533.CrossRefPubMedPubMedCentral

13.

Bolin C, Tawara K, Sutherland C, Redshaw J, Aranda P, Moselhy J, et al. Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation. Genes Cancer. 2012;3(2):117–30. https://doi.org/10.1177/1947601912458284.CrossRefPubMedPubMedCentral

14.

Caffarel MM, Araujo A, Lawrie C, Lopez IA, Rezola R, Abaurrea A. New targets in triple negative breast cancer: role of oncostatin M receptor pathway. Ann Oncol (Meeting Abstract). 2017;28:1.

15.

Jorcyk CL, Holzer RG, Ryan RE. Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine. 2006;33(6):323–36. https://doi.org/10.1016/j.cyto.2006.03.004.CrossRefPubMed

16.

Holzer RG, Ryan RE, Tommack M, Schlekeway E, Jorcyk CL. Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2. Clin Exp Metastasis. 2004;21(2):167–76. https://doi.org/10.1023/B:CLIN.0000024760.02667.db.CrossRefPubMed

17.

Junk DJ, Bryson BL, Smigiel JM, Parameswaran N, Bartel CA, Jackson MW. Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene (Article). 2017;36(28):4001–13. https://doi.org/10.1038/onc.2017.33.CrossRef

18.

Douglas AM, Grant SL, Goss GA, Clouston DR, Sutherland RL, Begley CG. Oncostatin M induces the differentiation of breast cancer cells. Int J Cancer. 1998;75(1):64–73. https://doi.org/10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D.CrossRefPubMed

19.

Guo L, Chen C, Shi M, Wang F, Chen X, Diao D, et al. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene. 2013;32(45):5272–82. https://doi.org/10.1038/onc.2012.573.CrossRefPubMed

20.

Bryson BL, Junk DJ, Cipriano R, Jackson MW. STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence. Cell Cycle. 2017;16(4):319–34. https://doi.org/10.1080/15384101.2016.1259037.CrossRefPubMed

21.

West NR, Murray JI, Watson PH. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene (Article). 2014;33(12):1485–94. https://doi.org/10.1038/onc.2013.105.CrossRef

22.

Tawara K, Scott H, Emathinger J, Ide A, Fox R, Greiner D, et al. Co-Expression of VEGF and IL-6 family cytokines is associated with decreased survival in HER2 negative breast cancer patients: subtype-specific IL-6 family cytokine-mediated VEGF secretion. Transl Oncol. 2019;12(2):245–55. https://doi.org/10.1016/j.tranon.2018.10.004.CrossRefPubMed

23.

Tawara K, Bolin C, Sutherland C, Anderson RL, Jorcyk CL. A role for oncostatin M in breast cancer metastasis to bone. Clin Exp Metastasis (Meeting Abstract). 2011;28:190–1.

24.

Kim Y, Stolarska MA, Othmer HG. The role of the microenvironment in tumor growth and invasion. Prog Biophys Mol Biol. 2011;106(2):353–79. https://doi.org/10.1016/j.pbiomolbio.2011.06.006.CrossRefPubMedPubMedCentral

25.

Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37. https://doi.org/10.1038/nm.3394.CrossRefPubMedPubMedCentral

26.

Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15(12):786–801. https://doi.org/10.1038/nrm3904.CrossRefPubMedPubMedCentral

27.

Friedl P, Brocker EB. The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci. 2000;57(1):41–64. https://doi.org/10.1007/s000180050498.CrossRefPubMed

28.

Albrechtsen R, Wewer UM, Liotta LA. Basement-membranes in human cancer. Pathol Annu. 1986;21:251–76.PubMed

29.

Siegal GP, Barsky SH, Terranova VP, Liotta LL. Stages of neoplastic transformation of human breast tissue as monitored by dissolution of basement membrane components an immuno peroxidase study. Invasion Metastasis. 1981;1(1):54–70.PubMed

30.

Werb Z, Lu P. The role of stroma in tumor development. Cancer J. 2015;21(4):250–3. https://doi.org/10.1097/PPO.0000000000000127.CrossRefPubMedPubMedCentral

31.

Li J, Lau GKK, Chen LL, Dong SS, Lan HY, Huang XR, et al. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One (Article). 2011;6(9):e21816.CrossRef

32.

Tsai CY, Wang CS, Tsai MM, Chi HC, Cheng WL, Tseng YH, et al. Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. Clin Cancer Res (Article). 2014;20(9):2276–88. https://doi.org/10.1158/1078-0432.CCR-13-1221.CrossRef

33.

Ma JH, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal (Review). 2020;18(13):33.CrossRef

34.

Hollosi P, Yakushij JK, Fong KSK, Csiszar K, Fong SFT. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells. Int J Cancer. 2009;125(2):318–27. https://doi.org/10.1002/ijc.24308.CrossRefPubMed

35.

Erler JT, Weaver VM. Three-dimensional context regulation of metastasis. Clin Exp Metastasis. 2009;26(1):35–49. https://doi.org/10.1007/s10585-008-9209-8.CrossRefPubMed

36.

Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 1996;149:273–82.PubMedPubMedCentral

37.

Malik R, Lelkes PI, Cukierman E. Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. Trends Biotechnol (Review). 2015;33(4):230–6. https://doi.org/10.1016/j.tibtech.2015.01.004.CrossRef

38.

Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res (Article). 2011;71(5):1561–72. https://doi.org/10.1158/0008-5472.CAN-10-2868.CrossRef

39.

Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009–U1107. https://doi.org/10.1038/nm.2208.CrossRefPubMed

40.

Wu SF, Zheng QD, Xing XX, Dong YY, Wang YH, You Y, et al. Matrix stiffness-upregulated LOXL2 promotes fibronectin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist pre-metastatic niche formation. J Exp Clin Cancer Res (Article). 2018;37(12):99.CrossRef

41.

Ahn SG, Dong SM, Oshima A, Kim WH, Lee HM, Lee SA, et al. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Breast Cancer Res Treat (Article). 2013;141(1):89–99. https://doi.org/10.1007/s10549-013-2662-3.CrossRef

42.

Kirschmann DA, Seftor EA, Fong SFT, Nieva DRC, Sullivan CM, Edwards EM, et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res. 2002;62(15):4478–83.PubMed

43.

Weidenfeld K, Schif-Zuck S, Abu-Tayeh H, Kang K, Kessler O, Weissmann M, et al. Dormant tumor cells expressing LOXL2 acquire a stem-like phenotype mediating their transition to proliferative growth. Oncotarget. 2016;7(44):71362–77. https://doi.org/10.18632/oncotarget.12109.CrossRefPubMedPubMedCentral

44.

Blockhuys S, Wittung-Stafshede P. Roles of copper-binding proteins in breast cancer. Int J Mol Sci (Review). 2017;18(10):871.CrossRef

45.

Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol. 2001;70:1–32.CrossRefPubMed

46.

Rucker RB, Kosonen T, Clegg MS, Mitchell AE, Rucker BR, Uriu-Hare JY, et al. Copper, lysyl oxidase, and extracellular matrix protein cross-linking. Ame J Clin Nutr. 1998;67(5):996S–1002S. https://doi.org/10.1093/ajcn/67.5.996S.CrossRef

47.

Moon HJ, Finney J, Ronnebaum T, Mure M. Human lysyl oxidase-like 2. Bioorg Chem (Article). 2014;57:231–41. https://doi.org/10.1016/j.bioorg.2014.07.003.CrossRef

48.

Wong CC-L, Tse AP-W, Huang Y-P, Zhu Y-T, Chiu DK-C, Lai RK-H, et al. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology. 2014;60(5):1645–58. https://doi.org/10.1002/hep.27320.CrossRefPubMed

49.

Kober KI, Cano A, Geraud C, Sipila K, Mobasseri SA, Philippeos C, et al. Loxl2 is dispensable for dermal development, homeostasis and tumour stroma formation. PLoS One (Article). 2018;13(18):e0199679.CrossRef

50.

Moon HJ, Finney J, Xu L, Moore D, Welch DR, Mure M. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. J Biol Chem (Article). 2013;288(42):30000–8. https://doi.org/10.1074/jbc.C113.502310.CrossRef

51.

Grossman M, Ben-Chetrit N, Zhuravlev A, Afik R, Bassat E, Solomonov I, et al. Tumor cell invasion can be blocked by modulators of collagen fibril alignment that control assembly of the extracellular matrix. Cancer Res (Article). 2016;76(14):4249–58. https://doi.org/10.1158/0008-5472.CAN-15-2813.CrossRef

52.

Han W, Chen S, Yuan W, Fan Q, Tian J, Wang X, et al. Oriented collagen fibers direct tumor cell intravasation. Proc Natl Acad Sci U S A. 2016;113(40):11208–13. https://doi.org/10.1073/pnas.1610347113.CrossRefPubMedPubMedCentral

53.

Sander LM. Modeling contact guidance and invasion by cancer cells. Cancer Res. 2014;74(17):4588–96. https://doi.org/10.1158/0008-5472.CAN-13-3294.CrossRefPubMed

54.

Cuevas EP, Eraso P, Mazon MJ, Santos V, Moreno-Bueno G, Cano A, et al. LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway. Sci Rep (Article). 2017;7(11):44988.CrossRef

55.

Peinado H, Iglesias-de la Cruz MD, Olmeda D, Csiszar K, Fong KSK, Vega S, et al. A molecular role for lysyl oxidase-like 2 enzyme in Snail regulation and tumor progression. Embo J. 2005;24(19):3446–58. https://doi.org/10.1038/sj.emboj.7600781.CrossRefPubMedPubMedCentral

56.

Moreno-Bueno G, Salvador F, Martin A, Floristan A, Cuevas EP, Santos V, et al. Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. Embo Mol Med (Article). 2011;3(9):528–44. https://doi.org/10.1002/emmm.201100156.CrossRef

57.

Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods (Article). 2020;17(3):261–72. https://doi.org/10.1038/s41592-019-0686-2.CrossRef

58.

van de Vijver MJ, He YD, van ‘t Veer LJ, Dai H, Hart AAM, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med. 2002;347(25):1999–2009. https://doi.org/10.1056/NEJMoa021967.CrossRefPubMed

59.

Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal. 2003;43:121–37 Pii s0167-9473(02)00225-6.CrossRef

60.

Aranda PS, LaJoie DM, Jorcyk CL. Bleach gel: a simple agarose gel for analyzing RNA quality. Electrophoresis (Article). 2012;33(2):366–9. https://doi.org/10.1002/elps.201100335.CrossRef

61.

Palamakumbura AH, Trackman PC. A fluorometric assay for detection of lysyl oxidase enzyme activity in biological samples. Anal Biochem. 2002;300(2):245–51. https://doi.org/10.1006/abio.2001.5464.CrossRefPubMed

62.

Barritault D, Expertbezancon A, Guerin MF, Hayes D. Use of acetone precipitation in isolation of ribosomal-proteins. Eur J Biochem. 1976;63(1):131–5. https://doi.org/10.1111/j.1432-1033.1976.tb10215.x.CrossRefPubMed

63.

Suzuki K, Bose P, Leong-Quong RY, Fujita DJ, Riabowol K. REAP: a two minute cell fractionation method. BMC Res Notes. 2010;3(1):294. https://doi.org/10.1186/1756-0500-3-294.CrossRefPubMedPubMedCentral

64.

de Jong OG, van Balkom BWM, Gremmels H, Verhaar MC. Exosomes from hypoxic endothelial cells have increased collagen crosslinking activity through up-regulation of lysyl oxidase-like 2. J Cell Mol Med (Article). 2016;20(2):342–50. https://doi.org/10.1111/jcmm.12730.CrossRef

65.

Barker HE, Bird D, Lang G, Erler JT. Tumor-secreted LOXL2 activates fibroblasts through FAK signaling. Mol Cancer Res (Article). 2013;11(11):1425–36. https://doi.org/10.1158/1541-7786.MCR-13-0033-T.CrossRef

66.

Brightman AO, Rajwa BP, Sturgis JE, McCallister ME, Robinson JP, Voytik-Harbin SL. Time-lapse confocal reflection microscopy of collagen fibrillogenesis and extracellular matrix assembly in vitro. Biopolymers. 2000;54(3):222–34. https://doi.org/10.1002/1097-0282(200009)54:3<222::AID-BIP80>3.0.CO;2-K.CrossRefPubMed

67.

Kaufman LJ, Brangwynne CP, Kasza KE, Filippidi E, Gordon VD, Deisboeck TS, et al. Glioma expansion in collagen I matrices: Analyzing collagen concentration-dependent growth and motility patterns. Biophys J. 2005;89(1):635–50. https://doi.org/10.1529/biophysj.105.061994.CrossRefPubMedPubMedCentral

68.

Bredfeldt JS, Liu Y, Conklin MW, Keely PJ, Mackie TR, Eliceiri KW. Automated quantification of aligned collagen for human breast carcinoma prognosis. J Pathol Inform. 2014;5:28.CrossRefPubMedPubMedCentral

69.

Liu Y, Keikhosravi A, Mehta GS, Drifka CR, Eliceiri KW. Methods for quantifying fibrillar collagen alignment. Fibrosis Methods Protoc. 2017;1627:429–51.CrossRef

70.

Tawara K, Scott H, Emathinger J, Wolf C, LaJoie D, Hedeen D, et al. HIGH expression of OSM and IL-6 are associated with decreased breast cancer survival: synergistic induction of IL-6 secretion by OSM and IL-1beta. Oncotarget. 2019;10(21):2068–85. https://doi.org/10.18632/oncotarget.26699.CrossRefPubMedPubMedCentral

71.

West NR, Murphy LC, Watson PH. Oncostatin M suppresses oestrogen receptor-alpha expression and is associated with poor outcome in human breast cancer. Endocr Relat Cancer. 2012;19(2):181–95. https://doi.org/10.1530/ERC-11-0326.CrossRefPubMed

72.

Blanchard F, Wang YP, Kinzie E, Duplomb L, Godard A, Baumann H. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. J Biol Chem (Article). 2001;276(50):47038–45. https://doi.org/10.1074/jbc.M107971200.CrossRef

73.

Lan YW, Theng SM, Huang TT, Choo KB, Chen CM, Kuo HP, et al. Oncostatin M-preconditioned mesenchymal stem cells alleviate bleomycin-induced pulmonary fibrosis through paracrine effects of the hepatocyte growth factor. Stem Cells Transl Med (Article). 2017;6(3):1006–17. https://doi.org/10.5966/sctm.2016-0054.CrossRef

74.

Kamiya A, Kinoshita T, Ito Y, Matsui T, Morikawa Y, Senba E, et al. Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer. Embo J (Article). 1999;18(8):2127–36. https://doi.org/10.1093/emboj/18.8.2127.CrossRef

75.

Akoglu H. User’s guide to correlation coefficients. Turk J Emerg Med. 2018;18(3):91–3. https://doi.org/10.1016/j.tjem.2018.08.001.CrossRefPubMedPubMedCentral

76.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (Article). 2006;10(6):515–27. https://doi.org/10.1016/j.ccr.2006.10.008.CrossRef

77.

Casneuf T, Axel AE, King P, Alvarez JD, Werbeck JL, Verhulst T, et al. Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-positive breast cancer. Breast Cancer Targets Ther (Article). 2016;8:13–27.

78.

Wagnerand M, Wiig H. Tumor interstitial fluid formation, characterization, and clinical implications. Front Oncol (Review). 2015;5(12):115.

79.

Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Wielenga VT, et al. Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics. Oncoimmunology (Article). 2016;5(14):e1248015.CrossRef

80.

Underhill-Day N, Heath JK. Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel. Cancer Res (Article). 2006;66(22):10891–901. https://doi.org/10.1158/0008-5472.CAN-06-1766.CrossRef

81.

May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res. 2011;13:202.CrossRefPubMedPubMedCentral

82.

Cano A, Santamaria PG, Moreno-Bueno G. LOXL2 in epithelial cell plasticity and tumor progression. Future Oncol (Review). 2012;8(9):1095–108. https://doi.org/10.2217/fon.12.105.CrossRef

83.

Kim Y-M, Kim E-C, Kim Y. The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol Biol Rep. 2011;38(1):145–9. https://doi.org/10.1007/s11033-010-0088-0.CrossRefPubMed

84.

Findlay AD, Foot JS, Buson A, Deodhar M, Jarnicki AG, Hansbro PM, et al. Identification and optimization of mechanism-based fluoroallylamine inhibitors of lysyl oxidase-like 2/3. J Med Chem. 2019;62(21):9874–89. https://doi.org/10.1021/acs.jmedchem.9b01283.CrossRefPubMed

85.

Chang J, Lucas MC, Leonte LE, Garcia-Montolio M, Singh LB, Findlay AD, et al. Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer. Oncotarget (Article). 2017;8(16):26066–78. https://doi.org/10.18632/oncotarget.15257.CrossRef

86.

Ryan RE, Martin B, Mellor L, Jacob RB, Tawara K, McDougal OM, et al. Oncostatin M binds to extracellular matrix in a bioactive conformation: Implications for inflammation and metastasis. Cytokine (Article). 2015;72(1):71–85. https://doi.org/10.1016/j.cyto.2014.11.007.CrossRef

87.

Peng DH, Ungewiss C, Tong P, Byers LA, Wang J, Canales JR, et al. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene (Article). 2017;36(14):1925–38. https://doi.org/10.1038/onc.2016.358.CrossRef

88.

Plotnikov SV, Waterman CM. Guiding cell migration by tugging. Curr Opin Cell Biol (Article). 2013;25(5):619–26. https://doi.org/10.1016/j.ceb.2013.06.003.CrossRef

89.

Shukla VC, Higuita-Castro N, Nana-Sinkam P, Ghadiali SN. Substrate stiffness modulates lung cancer cell migration but not epithelial to mesenchymal transition. J Biomed Mater Res Part A (Article). 2016;104(5):1182–93. https://doi.org/10.1002/jbm.a.35655.CrossRef

90.

Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MRE, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med (Article). 2002;347(12):886–94. https://doi.org/10.1056/NEJMoa013390.CrossRef

91.

Ursin G, Hovanessian-Larsen L, Parisky YR, Pike MC, Wu AH. Greatly increased occurrence of breast cancers in areas of mammographically dense tissue. Breast Cancer Res (Article). 2005;7(5):R605–8. https://doi.org/10.1186/bcr1260.CrossRef

92.

Roeder BA, Kokini K, Sturgis JE, Robinson JP, Voytik-Harbin SL. Tensile mechanical properties of three-dimensional type I collagen extracellular matrices with varied microstructure. J Biomech Eng Trans Asme (Article). 2002;124(2):214–22. https://doi.org/10.1115/1.1449904.CrossRef

93.

Kucia-Tran JA, Tulkki V, Smith S, Scarpini CG, Hughes K, Araujo AM, et al. Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. Br J Cancer. 2016;115(2):212–22. https://doi.org/10.1038/bjc.2016.199.CrossRefPubMedPubMedCentral

94.

Li Q, Zhu J, Sun F, Liu L, Liu X, Yue Y. Oncostatin M promotes proliferation of ovarian cancer cells through signal transducer and activator of transcription 3. Int J Mol Med. 2011;28(1):101–8. https://doi.org/10.3892/ijmm.2011.647.CrossRefPubMed

95.

Smith DA, Kiba A, Zong Y, Witte ON. Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues. Mol Cancer Res. 2013;11(10):1159–65. https://doi.org/10.1158/1541-7786.MCR-13-0238.CrossRefPubMedPubMedCentral

96.

Wang M-L, Pan C-M, Chiou S-H, Chen W-H, Chang H-Y, Lee OK-S, et al. Oncostatin M modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect. Cancer Res. 2012;72(22):6051–64. https://doi.org/10.1158/0008-5472.CAN-12-1568.CrossRefPubMed

97.

Pollack V, Sarkoezi R, Banki Z, Feifel E, Wehn S, Gstraunthaler G, et al. Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signaling. Am J Physiol Ren Physiol. 2007;293(5):F1714–26. https://doi.org/10.1152/ajprenal.00130.2007.CrossRef

Title: Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment
Authors: Simion C. Dinca
Daniel Greiner
Keren Weidenfeld
Laura Bond
Dalit Barkan
Cheryl L. Jorcyk
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Breast Cancer
Breast Cancer
Cytokines
Published in: Breast Cancer Research / Issue 1/2021
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/s13058-021-01430-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant

Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study

AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer

Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Self-reported arm and shoulder problems in breast cancer survivors in Sub-Saharan Africa: the African Breast Cancer-Disparities in Outcomes cohort study

Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer